Cutaneous PTCL-nos (CD8+ or CD56+ and cytotoxic marker)

Clinical trials for Cutaneous PTCL-nos (CD8+ or CD56+ and cytotoxic marker) explained in plain language.

Never miss a new study

Get alerted when new Cutaneous PTCL-nos (CD8+ or CD56+ and cytotoxic marker) trials appear

Sign up with your email to follow new studies for Cutaneous PTCL-nos (CD8+ or CD56+ and cytotoxic marker), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for rare blood cancers: first human trial launches

Disease control Recruiting now

This study tests a new drug called DR-01 in adults with rare types of leukemia or lymphoma. The goal is to see if it is safe and can shrink tumors. About 200 people will take part in this early-stage trial.

Matched conditions: CUTANEOUS PTCL-NOS (CD8+ OR CD56+ AND CYTOTOXIC MARKER)

Phase 1/2 • Sponsor: Dren Bio • Aim: Disease control

Last updated Jun 27, 2026 14:00 UTC

Cutaneous PTCL-nos (CD8+ or CD56+ and cytotoxic marker)

Get alerted when new Cutaneous PTCL-nos (CD8+ or CD56+ and cytotoxic marker) trials appear

New hope for rare blood cancers: first human trial launches